Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study.

CONCLUSIONS: Duvelisib demonstrated high response rates with good durability and a manageable safety profile in patients with R/R CLL/SLL who progressed on ofatumumab, including patients with high-risk disease and disease previously refractory to ofatumumab. PMID: 31964785 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31964785?dopt=Abstract

Source: Clinical Cancer Research - January 20, 2020 Category: Cancer & Oncology Authors: Davids MS, Kuss BJ, Hillmen P, Montillo M, Moreno C, Essell J, Lamanna N, Nagy Z, Tam CS, Stilgenbauer S, Ghia P, Delgado J, Lustgarten S, Weaver D, Youssoufian H, Jäger U Tags: Clin Cancer Res Source Type: research